Clinical predictors of rectal cancer response after neo-adjuvant (Chemo)Radiotherapy in Australia and New Zealand: Analysis of the Bi-National Colorectal Cancer Audit (BCCA)
Date
2023
Authors
Liu, J.
Lee, J.Y.T.
Bedrikovetski, S.
Traeger, L.
Moore, J.W.
Perry, J.L.
Kroon, H.M.
Sammour, T.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
European Journal of Surgical Oncology, 2023; 49(11):107070-1-107070-5
Statement of Responsibility
Jianliang Liu, Justin Y.T. Lee, Sergei Bedrikovetski, Luke Traeger, James W. Moore, Joanne L. Perry, Hidde M. Kroon, Tarik Sammour
Conference Name
Abstract
Pathological complete response (pCR) is observed in 11–26% of locally advanced rectal cancers undergoing neoadjuvant chemoradiotherapy (nCRT). This study aims to determine pCR rates and clinicopathological predictors in the Australian and New Zealand (ANZ) cohort. The Bi-National Colorectal Cancer Audit (BCCA) was interrogated for all rectal cancer patients who underwent nCRT prior to surgical resection between 2007 and 2020. Patients were divided in two groups: pCR (AJCC tumour regression grade 0) and partial/no response (pPR, regression grade 1,2 or 3). In total, 3230 patients were included. Rates of pCR and pPR were 704 (21.8%) and 2526 (78.2%), respectively. Long-course nCRT (p < 0.0001), lower clinical tumour stage (cT; p < 0.0001), and nodal stage (cN; p = 0.003) were associated with pCR on univariate analysis. On multivariable analysis, cN0 stage and long-course nCRT remained independent factors for a pCR. Awareness of these predictors provides valuable information when counseling patients regarding prognosis and treatment options.
School/Discipline
Dissertation Note
Provenance
Description
Available online 9 September 2023
Access Status
Rights
Crown Copyright © 2023 Published by Elsevier Ltd. All rights reserved.